{"filing":{"accession_number":"0001437749-26-020154","cik":"0000811641","ticker":"ICCC","company_name":"IMMUCELL CORP /DE/","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"iccc20260608_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926020154/iccc20260608_8k.htm"},"events":[{"id":5728,"run_id":5018,"accession_number":"0001437749-26-020154","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"ImmuCell's Board authorized a significant manufacturing capacity expansion program involving ~$3.5 million in Phase 1 capital investment and strategic repurposing of facilities to shift from Re-Tain® to First Defense® production. This represents a material strategic and operational decision affecting the company's manufacturing footprint and capital allocation, but does not fit neatly into the standard 8-K event taxonomy (not M\u0026A, not an impairment, not an executive change). The disclosure is material to investors assessing the company's growth strategy and capital deployment.","company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5812,"accession_number":"0001437749-26-020154","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"ImmuCell's Board authorized a significant manufacturing capacity expansion program involving ~$3.5 million in Phase 1 capital investment and strategic repurposing of facilities to shift from Re-Tain® to First Defense® production. This represents a material strategic and operational decision affecting the company's manufacturing footprint and capital allocation, but does not fit neatly into the standard 8-K event taxonomy (not M\u0026A, not an impairment, not an executive change). The disclosure is material to investors assessing the company's growth strategy and capital deployment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:15.896519+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5812,"accession_number":"0001437749-26-020154","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"ImmuCell's Board authorized a significant manufacturing capacity expansion program involving ~$3.5 million in Phase 1 capital investment and strategic repurposing of facilities to shift from Re-Tain® to First Defense® production. This represents a material strategic and operational decision affecting the company's manufacturing footprint and capital allocation, but does not fit neatly into the standard 8-K event taxonomy (not M\u0026A, not an impairment, not an executive change). The disclosure is material to investors assessing the company's growth strategy and capital deployment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:15.896519+00:00","company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","filing_date":"2026-06-10"}]}